Biogen Inc. (BIIB)
$
175.78
+1.68 (0.96%)
Key metrics
Financial statements
Free cash flow per share
15.5348
Market cap
26.7 Billion
Price to sales ratio
2.6538
Debt to equity
0.3619
Current ratio
2.7163
Income quality
1.5254
Average inventory
2.2 Billion
ROE
0.0925
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Biogen Inc. is a leader in discovering, developing, manufacturing, and delivering innovative therapies for neurological and neurodegenerative diseases. The portfolio includes treatments such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS), SPINRAZA for spinal muscular atrophy, and FUMADERM for plaque psoriasis. Additionally, the company offers BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. Furthermore, RITUXAN is provided for non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA also targets non-Hodgkin's lymphoma and CLL, while GAZYVA treats CLL and follicular lymphoma. OCREVUS is available for relapsing MS and primary progressive MS, alongside various anti-CD20 therapies. The company's pipeline includes promising candidates such as BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 for Alzheimer's disease and dementia; and BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 targeting neuromuscular disorders. Biogen also develops treatments for Parkinson's disease, neuropsychiatric conditions, immunological diseases, acute neurology, and neuropathic pain, alongside a range of biosimilars under development. The company has established collaborations and license agreements with notable entities such as Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, and Genentech, Inc. Biogen Inc. earned an interest income of $67,600,000.00 showcasing its financial investments, and reported an income before tax of $1,906,000,000.00 demonstrating its pre-tax profitability. The net income ratio is 0.17 reflecting the company's profitability margin, while the EBITDA is $2,995,700,000.00 a key indicator of its operational profitability. Additionally, the operating income ratio is 0.26 indicating solid operational performance. The stock is reasonably priced at $142.50 appealing to a broad range of investors. With a high average trading volume of 1,822,469.00 the stock indicates strong liquidity, and Biogen holds a mid-range market capitalization of $25,787,325,372.00 marking it as a steady performer in the market. It is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape, and it operates within the Healthcare sector, driving innovation and growth. This combination of factors makes Biogen an attractive option for stakeholders seeking opportunities in the pharmaceutical sector, particularly in neurological treatment advancements.
Is Biogen Inc. (BIIB) a good investment?
Investing in Biogen Inc. (BIIB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Biogen Inc. (BIIB)'s stock forecast?
Analysts predict Biogen Inc. stock to fluctuate between $110.04 (low) and $185.17 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Biogen Inc.'s market capitalization?
As of 2025-12-15, Biogen Inc.'s market cap is $25,787,325,372, based on 146,702,272 outstanding shares.
How does Biogen Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Biogen Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Biogen Inc. (BIIB) stock?
To buy Biogen Inc. (BIIB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BIIB. Place an order (Market, Limit, etc.).
What is the best time to invest in Biogen Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Biogen Inc. stock ever split?
Biogen Inc.'s last stock split was 3:1 on 2001-01-18.
How did Biogen Inc. perform in the last earnings report?
Revenue: $9,675,900,000 | EPS: $11.20 | Growth: 39.65%.
Where can I find Biogen Inc.'s investor relations reports?
Visit https://www.biogen.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Biogen Inc.?
You can explore historical data from here
What is the all-time high and low for Biogen Inc. stock?
All-time high: $351.86 (2021-08-18) | All-time low: $110.04 (2025-04-09).
What are the key trends affecting Biogen Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China.
seekingalpha.com
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
seekingalpha.com
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
businesswire.com
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations from studies of zorevunersen at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia. Zorevunersen is an investigational antisense oligonucleotide currently being evaluat.
proactiveinvestors.com
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) could see its stock move higher over the next two years as progress on its Alzheimer's drug Leqembi and a series of late-stage pipeline readouts draw more investor attention, according to Jefferies. The broker, which rates the stock Buy with a price target of $210, said Leqembi's trajectory in early Alzheimer's disease “could accelerate” if a subcutaneous induction version wins approval in mid-2026, enabling full at-home use.
zacks.com
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
benzinga.com
Biogen Inc. (NASDAQ: BIIB) stock traded higher after Novo Nordisk A/S (NYSE: NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.
businesswire.com
TORONTO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious diseases. The company has secured more than $70 million in committed funding, including a collaboration with Biogen Inc. that will provide $50 million in upfront capital, as well as an equity commitment from Versant. Dayra emerged from Versant's Frontier Discovery Engine that spans Toronto and Montreal. F.
barrons.com
The drugmaker announces that Ozempic didn't slow the progression of Alzheimer's in two clinical trials.
globenewswire.com
CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4 in San Diego. Data on LEQEMBI® (lecanemab-irmb) will include findings on subcutaneous administration for initiation dosing, the benefits of continued therapy and estimated time savings over 10 years of treatment based on Phase 3 clinical data, and real-world experience from a post-marketing observational study in Japan and the ALZ-NET registry. The company will also share new insights into BIIB080, an investigational antisense oligonucleotide (ASO) therapy, from a healthy-volunteer biodistribution study, as well as research that helps inform understanding of disease progression.
See all news
